2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Poly-ICLC: new trials by email Literature Review of Poly-ICLC trials Research Report on Poly-ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Poly-ICLC - Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | Nina Bhardwaj | 8 | 2013-11-01 | 2018-01-23 |
Breast Neoplasms (1) · Fallopian Tube Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
National Cancer Institute (NCI) (1) · Nina Bhardwaj (1)
United States (2)
Kunle Odunsi (1) · Nina Bhardwaj, MD, PhD (1)
P30CA016056 (1)